Novo denecimig positive long term safety, efficacy in phase 3 for hemophilia A

 

• Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly dosing in hemophilia A participants of all ages and disease severities1,2
• Denecimig is an investigational subcutaneous FVIIIa-mimetic antibody under review with the US Food and Drug Administration (FDA)1
• Separate phase 3 explorer10 data observed that concizumab reduced annualized bleeding rate compared to on-demand treatment in children with hemophilia A or B, with inhibitors

https://www.prnewswire.com/news-releases/novo-nordisks-denecimig-mim8-demonstrated-positive-results-in-long-term-safety-and-efficacy-in-phase-3-hemophilia-a-frontier-extension-study-at-isth-2026-302823063.html